NCT03653208View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetic Characteristics of hzVSF-v13 in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

November 20, 2018

Primary Completion Date

February 29, 2020

Study Completion Date

February 29, 2020

Conditions
Healthy
Interventions
DRUG

hzVSF-v13

Dosage form: 10mg / 20mg / 50mg / 100mg / 200mg / 400mg / 800mg / 1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1 (single administration)

DRUG

Placebo

Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1 (single administration)

Trial Locations (1)

03080

Seoul National University Hospital, Seoul

Sponsors

Lead Sponsor

ImmuneMed, Inc.
All Listed Sponsors
lead

ImmuneMed, Inc.

INDUSTRY

NCT03653208 - Safety, Tolerability, Pharmacokinetic Characteristics of hzVSF-v13 in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter